MedPath

Prospective observational study to clarify the effect of pneumococcal vaccine in interstitial lung disease patients with immunosuppressive therapy

Not Applicable
Conditions
interstitial lung disease
Registration Number
JPRN-UMIN000015225
Lead Sponsor
Sapporo medical university Respiratory medicine and allergology
Brief Summary

IgG concentrations to serotype 19F were increased in all groups in response to the vaccine. Both PCV13 and PPSV23 induced IgG concentrations in patients immunized for the first time. Response rates for the ILD group were comparable with those for the ILD group undergoing corticosteroid therapy. Only idiopathic pulmonary fibrosis patients undergoing immunosuppressive therapy had a significantly lower response.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
150
Inclusion Criteria

Not provided

Exclusion Criteria

Patients who are vaccinated with pneumococcal vaccine within the last year

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
We measure opsonic activity (OPA) and the rise of the antibody titer of the before and after vaccination. We compare antibody titers, the rise of OPA in the non-treatment group and the immunosuppressive therapy group.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath